Example: Heart Attack

Search clinical trials for: Lenalidomide

Total 1010 results

NCT03647124

Recruiting

Non-Interventional Study in Patients With Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) to Investigate the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden

Conditions: Lymphoma, Mantle-Cell
NCT03701711

Recruiting

Lenalidomide in Anti-MAG Neuropathy: Phase 1b Study

Conditions: Demyelinating Sensorimotor Neuropathy
NCT02371577

Withdrawn

Evaluation of the Immune Restoration Potential Of Lenalidomide

Conditions: Chronic Lymphocytic Leukemia (CLL)
NCT02370888

Terminated

Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease

Conditions: Leukemia, Myeloid; Myelodysplastic Syndromes
NCT02302469

Completed

Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia

Conditions: Waldenstrom Macroglobulinemia
NCT02279654

Active, not recruiting

Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)

Conditions: Myelodysplastic Syndrome
NCT02538965

Completed

A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Conditions: Leukemia, Myeloid
NCT04796857

Recruiting

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

Conditions: Non-GCB/ABC Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma; Follicular Lymphoma Grade IIIb; Transformed Lymphoma; EBV-Positive DLBCL, Nos; ALK-Positive Anaplastic Large Cell Lymphoma
NCT04109872

Recruiting

Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.

Conditions: Mantle Cell Lymphoma
NCT04622579

Recruiting

Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years

Conditions: Diffuse Large B Cell Lymphoma; Age Over 80 Years
NCT03730740

Recruiting

Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell Lymphoma

Conditions: Relapsed and/or Refractory Non-Hodgkin T-cell Lymphoma
NCT01750762

Terminated

Lenalidomide After Allo Transplant

Conditions: Multiple Myeloma; Lymphoma
NCT04113226

Not yet recruiting

Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma

Conditions: Chemotherapy; Diffuse Large B-Cell Lymphoma (DLBCL), Nos; Elderly
NCT02018523

Terminated

Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer

Conditions: Carcinoma, Non-Small-Cell Lung
NCT04544059

Not yet recruiting

Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma

Conditions: Diffuse Large B Cell Lymphoma
NCT04432402

Recruiting

Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

Conditions: Diffuse Large B Cell Lymphoma
NCT03302728

Recruiting

Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma

Conditions: Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Hodgkin Lymphoma
NCT02963610

Terminated

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

Conditions: Relapsed or Refractory Solid Tumors; Nonsmall Cell Lung Cancer
NCT01724177

Completed

A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

Conditions: Adult T-Cell Leukemia-Lymphoma
NCT01198054

Terminated

LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)

Conditions: AML
NCT03208218

Completed

Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers

Conditions: Healthy, Male
NCT00847639

Completed

Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma

Conditions: Multiple Myeloma
NCT02155634

Withdrawn

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Conditions: Multiple Myeloma; Neoplasms; Plasma Cells; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Therapeutic Uses
NCT01264315

Active, not recruiting

Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant

Conditions: Multiple Myeloma
NCT01342172

Terminated

Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma

Conditions: Urinary Bladder Neoplasms